Drug Type Shared antigen vaccine, Therapeutic vaccine, mRNA vaccine |
Synonyms HER2 ECDTM VRP, HUHER2-ECD+TM, AVX 901 + [5] |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Phase 2 | US | - | 19 Feb 2019 |
HER2 Positive Breast Cancer | Phase 1 | US | 01 Feb 2012 | |
Metastatic breast cancer | Phase 1 | US | 01 Feb 2012 |
Phase 2 | 8 | (VRP-HER2 Vaccine) | muhkrxervl(hvspjofgbu) = tupprjlieb xhcttcqjyx (dqidgfyqzf, bstieqndna - vnacmfyryq) View more | - | 11 Dec 2024 | ||
(Pembrolizumab) | muhkrxervl(hvspjofgbu) = wctrumgrlf xhcttcqjyx (dqidgfyqzf, iehmyjlwjs - qrqwlsauvm) View more |